LUCKNOW, Sept. 25 -- Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), which has been selected to conduct the third phase of Covaxin's clinical trials, has decided to begin the same from mid-October.

Covaxin is India's first potential indigenous Covid-19 vaccine, jointly developed by the Indian Council of Medical Research (ICMR) and Bharat Biotech International Limited (BBIL).

SGPGIMS director RK Dhiman said: "PGI has been named the nodal organization, leading the trials in UP along with BRD Medical College, Gorakhpur."

He said: "The trials are expected to start from mid-October. Till then we will work on factors such as subject recruitment, ethics committee approvals, infrastructure to support the trials, qualified pr...